BackRecro Pharma Overview

Recro Pharma Goodwill

Latest goodwill for REPH: $41M.

Get informed when a big investor buys or sells

+ Follow
Goodwill
$41.08M
↑ 0.00% YoYΔ $0.00 vs prior year quarter

Peer average / median

Loading

Recro Pharma Goodwill History

Loading

Recro Pharma vs. peers: Goodwill Comparison

Loading

Recro Pharma Goodwill Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Recro Pharma (REPH) FAQ

As of the most recent data (December 2023), REPH shows a goodwill of $41M. That compares with $41M in the prior-year period — up 0.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, REPH's goodwill is now $41M (was $41M) — essentially flat versus a year earlier. Pairing that YoY change with peer averages gives a clearer picture of whether Recro Pharma is outperforming or lagging.

Tracking REPH's goodwill over time shows whether Recro Pharma is scaling, shrinking, or reshaping that part of the business. The current reading is $41M That compares with $41M in the prior-year period — up 0.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this goodwill page, Stockcircle has Recro Pharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect goodwill (currently $41M) with ownership activity and broader fundamentals.

Recro Pharma's goodwill is $41M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.